 |
Frederic Waldman, MD, PhD
Biographical Sketch
| BA, 1972, Williams College, Williamstown,
MA, Biology |
| PhD, 1980, New York University, New York,
NY, Cell Biology |
| MD, 1980, New York University, New York,
NY, Medicine |
| |
|
| 1980-1982 |
Resident, Department of Anatomic Pathology, University
of California, San Francisco, CA |
| 1982-1983 |
Resident, Department of Laboratory Medicine, University
of California, San Francisco, CA |
| 1983-1984 |
Chief Resident, Department of Laboratory Medicine, University
of California, San Francisco, CA |
| 1984-1991 |
Assistant Professor, Department of Laboratory Medicine,
University of California, San Francisco, CA |
| 1991-1997 |
Associate Professor, Department of Laboratory Medicine,
University of California, San Francisco, CA |
| 1997- Present |
Professor, Department of Laboratory Medicine, University
of California, San Francisco, CA |
| 2000- Present |
Director, Molecular Cytogenetics Core, Comprehensive
Cancer Center, University of California, San Francisco,
CA |
| 2001- Present |
Director, Immunohistochemistry Core, Comprehensive Cancer
Center, University of California, San Francisco, CA |
Fred Waldman attended Williams College and received his MD and
PhD at New York University Medical School. He then trained in
Pathology and Laboratory Medicine at the University of California
at San Francisco. He has been a faculty member at UCSF since 1984.
Waldman is currently Chair of the Integration Panel for the Department
of Defense Prostate Cancer Research Program. He is a member of
the Metabolic Pathology NIH Study Section, and participates in
numerous additional review groups. He is a Councilor of the International
Society of Analytical Cytology, and is Chair of their Scientific
Communications Committee.
Waldman has published over 150 scientific
papers and holds multiple patents in the field of molecular cytogenetics
(including one for Comparative Genomic Hybridization). He has
a long standing interest in applying tools of molecular cytogenetics
to analyze DNA purified from bladder and kidney tumors, in order
to identify new markers of cancer diagnosis and prognosis.
return
to top
|
|
|
|
|
|
